GLP-1 Microdosing Guide: What It Means, What We Know, and What Remains Uncertain
Written by Evergreen Editorial, Evergreen Telehealth
Medically reviewed by Dr. Casey Greene, PharmD, IFMCP, Peptide Subject Matter Expert, Evergreen Telehealth
Published Updated
Quick Answer
GLP-1 microdosing means taking a lower-than-standard dose of semaglutide or tirzepatide, usually weekly, most often for weight maintenance rather than weight loss. There is no standard definition, and we found no trial of doses below the approved range; the evidence for GLP-1 medicines comes from approved doses. Microdoses are typically compounded products, which are not FDA-approved, and your prescribing clinician decides whether one is appropriate.

Introduction
GLP-1 microdosing means taking a lower-than-standard dose of semaglutide or tirzepatide, usually as a small weekly injection, most often with the goal of maintaining weight or supporting metabolic health rather than losing weight. People search for it as "microdosing tirzepatide" or "microdosing semaglutide," and the idea has spread quickly on social media. It is not a defined medical regimen: there is no standard definition of a microdose, and the FDA-approved doses are the only ones that have been studied rigorously. (1)
This guide answers a practical question: what should I know before considering GLP-1 microdosing, and what might the process involve? It explains what microdosing means, how it differs from established dosing, what is known about weight maintenance, what remains uncertain, who may be a candidate, how it is administered, the main risks, and how it is monitored. It covers both tirzepatide and semaglutide. For the full background on these medicines, see The Complete Guide to GLP-1 Weight Loss Treatment →.
One point up front: the evidence for GLP-1 medicines comes from approved doses. Whether lower doses deliver the same benefits is largely untested, and this guide is clear about that throughout.
What Is GLP-1 Microdosing?
GLP-1 medications such as semaglutide and tirzepatide mimic a gut hormone that helps regulate appetite, digestion, and blood sugar. In an established regimen, the dose starts low and is increased gradually, for example every four weeks, toward a maintenance dose that was tested in clinical trials. (1) Microdosing departs from that pattern by staying at a small, steady dose, deliberately below the studied and approved range.
Evergreen's patient guide describes a GLP-1 microdose as a small, steady weekly dose of tirzepatide or semaglutide that stays the same each week. It uses the same type of medicine as a full GLP-1 plan at a lower dose, and it is not intended for weight loss. Compounded versions are not FDA-approved. People who use microdoses typically hope to maintain weight or support long-term metabolic health, which is how the body uses food for energy. Whether microdoses achieve this has not been tested in trials. The exact dose is personal and is set by your provider.
Two points help avoid confusion. First, the starting doses in approved regimens (such as the first weekly doses of semaglutide) are titration steps designed to let the body adjust, not doses studied as long-term treatment. Second, when a clinician adjusts an approved dose for tolerability, for example by pausing a dose increase, that is dose individualization under supervision, which physicians distinguish from microdosing. (1)
How Does Microdosing Differ From Established GLP-1 Dosing?
Studied doses vs. non-standard doses. FDA-approved tirzepatide products come in six weekly doses (2.5, 5, 7.5, 10, 12.5, and 15 mg), and the landmark weight-loss trials used 1.7 or 2.4 mg of semaglutide and 5, 10, or 15 mg of tirzepatide. (1) Microdoses fall below that range and have not been studied in trials.
Titration vs. a fixed small dose. Established regimens step up toward a maintenance dose. A microdose is typically held steady.
Approved products vs. compounded products. Approved GLP-1 medicines come in standardized pens or vials. Microdoses are typically prepared by compounding pharmacies, and compounded medicines are not FDA-approved. (2)
Goal. Established regimens target weight loss or glycemic control. Microdosing is used mostly for maintenance or metabolic support, which is a different and much less studied goal.
For a head-to-head look at the dosing approaches, see GLP-1 Microdosing vs. Standard GLP-1 Dosing →.
Why Might Someone Consider GLP-1 Microdosing?
People usually consider it for one or more of these reasons:
Maintaining weight after weight loss, especially after reaching a goal on a full-dose program.
Side effects at higher doses, such as nausea or fatigue, which can make a lower dose more appealing. See Managing Nausea During GLP-1 Treatment →.
Ongoing metabolic support, such as blood sugar and appetite regulation.
Some research on full-dose GLP-1 medicines has examined effects beyond weight and blood sugar, such as inflammation and cardiovascular events, in studies such as STEP 3 (10) and SELECT. (3) These benefits have not been shown at microdoses. Social media claims about microdosing and longevity or inflammation are unproven. (1)
What Is Known About Microdosing and Weight Maintenance?
The maintenance problem is real. When people stop GLP-1 medicines, weight tends to come back. In the extension of the STEP 1 trial, participants who stopped semaglutide regained about two-thirds of the weight they had lost within a year. (4) In the SURMOUNT-4 trial of tirzepatide, people who switched to placebo after 36 weeks regained weight, while those who continued the medicine kept losing. (5) That is why obesity is increasingly treated as a long-term condition.
But those two trials tested continuing the full approved dose. (4, 5) One later trial did test a reduced dose: in SURMOUNT-MAINTAIN, adults who had lost weight on tirzepatide were randomized for 52 weeks to continue the maximum tolerated dose, step down to 5 mg, or switch to placebo. Average weight change from the start of treatment by week 112 was about -21.9% with the maximum dose, -16.6% with 5 mg, and -9.9% with placebo. (11) Stepping down kept off more weight than stopping, but less than continuing, and 5 mg is still an approved dose, not a microdose. We did not find a randomized trial of doses below the approved range, and reviewers report there is no legitimate long-term data on microdosing for weight or any other condition. (1) What we do know about dose and effect points in a cautious direction: in the SURMOUNT-1 trial, average weight loss rose with the tirzepatide dose, from about 15% at 5 mg to about 19.5% at 10 mg and 20.9% at 15 mg over 72 weeks. (6) More drug generally produced more effect, so benefits at much lower doses cannot be assumed.
A clinician might still consider a lower-dose maintenance plan for a particular patient, for example after reaching a goal weight or if side effects limit higher doses, and monitor how it goes. That is a reasonable clinical judgment, but it is not the same as established evidence. For why weight maintenance matters, see Why Weight Maintenance Matters for Long-Term Metabolic Health →.
What Remains Uncertain?
Whether doses below the approved range maintain weight loss, and at what dose.
What the right dose is. There is no agreed definition or schedule.
Long-term safety of ongoing low-dose use.
Benefits beyond weight (inflammation, heart, brain, longevity) at low doses.
Product quality. Compounded products have not been studied for safety, effectiveness, or weight regain after stopping, and their contents can vary. (1, 7)
How to stop or step down safely after a period of treatment.
Microdosing Tirzepatide
Tirzepatide acts on two hormone pathways, GLP-1 and GIP, and is approved at six weekly doses for weight management. "Microdosing tirzepatide" refers to using a weekly dose below that approved range. Because tirzepatide's weight-loss effect increased with dose in trials, (6) the main open question is how much benefit a much lower dose preserves. Learn more about the medicine in Semaglutide vs. Tirzepatide →.
Microdosing Semaglutide
Semaglutide acts on the GLP-1 pathway and is approved for weight management at up to 2.4 mg weekly in its FDA-approved form and for diabetes at lower doses. "Microdosing semaglutide" refers to a weekly dose well below the weight-management dose. The same cautions apply: the trial evidence is for approved doses, and compounded products are not FDA-approved. The semaglutide you receive is also an individual product: the FDA has warned that some compounders use salt forms (such as semaglutide sodium or acetate) that are different active ingredients from those in approved drugs. (7)
Who May Be a Candidate for GLP-1 Microdosing?
A licensed clinician decides, based on your health history, goals, and medications. Microdosing is not intended for weight loss, and it is not appropriate for everyone. Factors that a clinician commonly weighs, based on Evergreen's patient guide for GLP-1 medicines, include:
Pregnancy or breastfeeding. GLP-1 medicines are not used during either, and a planned pregnancy should be discussed first.
Health history. Thyroid cancer in the family, pancreatitis, gallbladder problems, diabetes eye problems, or an eating disorder call for review, and bloodwork may be suggested.
Other medicines. Some diabetes medicines raise the risk of low blood sugar. Only one GLP-1 medicine should be used at a time.
Upcoming surgery. Tell your surgeon you take a GLP-1, since you may need to hold a dose.
This is not a complete list. Not everyone will be a candidate, and no one should start a compounded GLP-1 without a clinician's evaluation.
What Does the GLP-1 Microdosing Process Involve?
Programs differ, so ask any provider to explain their steps. In clinician-guided telehealth care, the general sequence tends to look like this:
Intake and clinical evaluation. You complete a health questionnaire covering your history, symptoms, medications, and goals.
Review of medical history. A licensed clinician decides whether a GLP-1 microdose is appropriate and which medicine fits.
Potential laboratory assessment. Some clinicians check bloodwork first, depending on your history. What Lab Tests May Be Used in Longevity Medicine? →
Individualized treatment decision. The clinician chooses the medicine, dose, and schedule. Doses are personal and are not listed in general guides.
Administration. Injections are self-given at home after instruction.
Follow-up. Evergreen's patient guide describes a required first check-in around three weeks in, and ongoing check-ins afterward. See What Should I Expect From a GLP-1 Prescription? →.
Program details and pricing are described on the Evergreen Longevity page →.
How Is GLP-1 Microdosing Administered?
Evergreen's patient guide describes a once-weekly shot just under the skin of the belly, thigh, or upper arm. Pick one day and stick with it. Keep things clean, use a new syringe every time, rotate injection sites, and keep the vial in the refrigerator (never frozen), discarding it 28 days after first use or by the beyond-use date on the label. Dispose of needles and syringes in a sharps container.
Accurate measuring matters more with compounded products. The FDA has received reports of adverse events, some requiring hospitalization, from dosing errors with compounded injectable semaglutide, often caused by confusion among milliliters, milligrams, and "units" when drawing from a multidose vial. (8) Ask your provider or pharmacy to state the dose in clear measurements, confirm that the syringe size matches the dose, and show you how to draw it up. If you miss a dose, follow your plan: Evergreen's guide says to take it if your next shot is at least two days away and to skip it otherwise, never doubling up, and to message your care team if more than 14 days have passed.
What Should You Know About Compounded GLP-1 Products?
Almost all microdosing uses compounded medicines. Compounded drugs do not go through the FDA's premarket review for safety, quality, or effectiveness, and the FDA states they should be used only when a patient's medical needs cannot be met by an available approved drug. (2, 8) That judgment belongs to your prescribing clinician, who decides, based on your individual medical needs, whether a compounded medicine or a commercially available product is appropriate. It should not be assumed by default. The FDA has also reported adverse events with compounded semaglutide and tirzepatide, including dosing errors and doses beyond what is on approved labels, and it notes that events are likely underreported. (7)
The regulatory landscape is also changing. FDA has declared the shortages of tirzepatide and semaglutide resolved, which narrowed the circumstances in which compounded preparations are allowed, and in April 2026 it proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list. (9) Ask your provider about the pharmacy that prepares your medicine and which form of the drug it contains. For the difference between pharmacy-compounded products and unregulated ones, read why peptide prices and quality vary so much →.
What Are the Potential Side Effects and Risks of GLP-1 Microdosing?
Because microdoses are lower than standard doses, side effects may be milder, but this has not been tested in trials, and the same medicines can still cause problems. Possible effects include mild nausea, vomiting, diarrhea, constipation, and redness where you inject. Less common but serious risks of GLP-1 medicines include pancreatitis and gallbladder problems. See What Are the Possible Side Effects of GLP-1s? → for detail.
Contact your care team for side effects that last or bother you, or if you plan surgery or start a new medicine. Call 911, go to the ER, or call your doctor right away for very bad belly pain that spreads to your back, a new neck lump with a hoarse voice or trouble swallowing, trouble breathing or swelling of the face, lips, tongue, or throat, a rash or hives with trouble breathing, confusion or fainting from low blood sugar (if on diabetes medicine), diarrhea with blood or a fever, upper right belly pain with fever or yellow skin, or inability to keep fluids down for more than a day.
How Is GLP-1 Microdosing Monitored?
Monitoring is how a plan is reviewed and adjusted over time. It typically involves regular check-ins about how you feel, side effects, weight changes, and any new medicines or health conditions. Lab tests may be used when they are clinically indicated, but specific testing and follow-up schedules vary by provider and no schedule is standard across programs. Monitoring also gives your clinician a basis to adjust the dose, which matters here because there is no evidence-based microdose to follow. How Are Longevity Treatment Results Monitored Over Time? →
How Long Might GLP-1 Microdosing Continue?
There is no trial-defined duration for microdosing. How long it continues depends on your goals, how you respond, how well you tolerate it, and what your clinician recommends after reassessing. Because weight tends to return after GLP-1 medicines are stopped, (4, 5) people sometimes continue long term, but any decision to continue, change, or stop should be made with your clinician. Evergreen's patient guide notes that some weight coming back after stopping is normal and says to talk with your care team before stopping. It can help to set a clear goal and revisit whether it is being met. See also How Long Until My GLP-1 Starts Working? →.
Frequently Asked Questions About GLP-1 Microdosing
Is GLP-1 microdosing FDA-approved? No. FDA-approved semaglutide and tirzepatide regimens use specific studied doses. Microdoses are typically compounded, and compounded medicines are not FDA-approved. (2) There is also no standard definition of a microdose.
Does microdosing GLP-1 cause weight loss? It is not intended to. People who use microdoses typically hope to maintain weight or support metabolic health, but whether microdoses achieve this has not been tested in trials. In trials, weight loss increased with dose, so lower doses should not be expected to match the results of full-dose programs. (6)
Is microdosing tirzepatide the same as microdosing semaglutide? They are different medicines. Tirzepatide acts on GLP-1 and GIP pathways, while semaglutide acts on GLP-1 only. Neither has been tested in trials at microdoses. Your clinician chooses based on your history and goals.
Will I regain weight if I stop? Often, yes. In trials of approved doses, people who stopped semaglutide or tirzepatide regained a significant share of the weight they had lost. (4, 5) Whether a lower dose changes that is not established.
Is microdosing safer than a full dose? Possibly fewer side effects, but this has not been demonstrated. Lower doses do not remove risks such as dosing errors or product-quality problems with compounded drugs. (7, 8)
Can I combine microdosing with other treatments? Only one GLP-1 should be used at a time. Combinations with other medicines should be reviewed by a clinician. Can Multiple Longevity Treatments Be Used Together? →
Explore GLP-1 Microdosing Through Evergreen Longevity
Evergreen Longevity is Evergreen's clinician-guided program for healthy aging. A licensed provider reviews your health history and goals and decides which approaches, if any, are appropriate, and treatment plans are individualized. If your main goal is weight loss, Evergreen Lean → is Evergreen's clinician-guided GLP-1 program. For the broader picture on longevity treatments, read The Complete Guide to Longevity Treatments and Healthy Aging →.
Explore Clinician-Guided Longevity Care. Learn how Evergreen Longevity approaches healthy aging through individualized protocols and ongoing provider monitoring. Explore Evergreen Longevity →
Not every applicant will qualify for GLP-1 microdosing or any other protocol.
References
1. No standard definition, no long-term data, approved doses:
STAT. GLP-1 microdosing is popular, but there's little evidence it works. May 29, 2026. https://www.statnews.com/2026/05/29/glp-1-microdose-popular-but-unsupported-by-evidence/
2. Compounded drugs and FDA approval:
U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers. https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers
3. Cardiovascular outcomes with semaglutide:
Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389(24):2221-2232. https://pubmed.ncbi.nlm.nih.gov/37952131/
4. Weight regain after stopping semaglutide:
Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes Obes Metab. 2022;24(8):1553-1564. https://pubmed.ncbi.nlm.nih.gov/35441470/
5. Continuing vs stopping tirzepatide:
Aronne LJ, Sattar N, Horn DB, et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial. JAMA. 2024;331(1):38-48. https://pubmed.ncbi.nlm.nih.gov/38078870/
6. Dose and weight loss with tirzepatide:
Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205-216. https://pubmed.ncbi.nlm.nih.gov/35658024/
7. FDA concerns with unapproved and compounded GLP-1 drugs:
U.S. Food and Drug Administration. FDA's concerns with unapproved GLP-1 drugs used for weight loss. https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
8. Dosing errors with compounded semaglutide:
U.S. Food and Drug Administration. FDA alerts health care providers, compounders and patients of dosing errors associated with compounded injectable semaglutide products. https://www.fda.gov/drugs/human-drug-compounding/fda-alerts-health-care-providers-compounders-and-patients-dosing-errors-associated-compounded
9. Shortage resolution and 503B bulks list proposal:
U.S. Food and Drug Administration. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize. https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize ; Stanford Medicine. Compounded GLP-1s: why doctors worry about safety. July 2026. https://med.stanford.edu/news/insights/2026/07/glp1s-compounded-why-doctors-worry-about-safety.html
10. Inflammatory markers with semaglutide (as cited in Evergreen's GLP-1 Main Guide):
Wadden TA, Bailey TS, Billings LK, et al. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial. JAMA. 2021;325(14):1403-1413. https://pubmed.ncbi.nlm.nih.gov/33625476/
11. Stepping down tirzepatide for weight maintenance:
Horn DB, Aronne LJ, Wharton S, et al. Tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN): a multicentre, double-blind, randomised, placebo-controlled trial. 2026. https://pubmed.ncbi.nlm.nih.gov/42119587/
This page is for educational purposes only and is not a substitute for individualized medical advice. Always consult a licensed healthcare provider before starting or stopping any medication. Information and statements on this material have not been evaluated by the Food and Drug Administration. Evergreen Telehealth content is for general education and should never replace professional medical advice that considers your individual health.
Medically reviewed by Dr. Casey Greene, PharmD, IFMCP, Peptide Subject Matter Expert, Evergreen Telehealth, on November 17, 2026.